GLP-1 medications come in two injectable formats: pre-filled single-use pens (like Wegovy and Zepbound) and multi-dose vials (common with compounded providers). The price difference is significant, but so are the safety and convenience tradeoffs.
Pre-Filled Pen: What You Pay For
Brand-name GLP-1 pens (Wegovy, Zepbound, Ozempic, Mounjaro) are pre-filled with a precise, single dose. You click, inject, and dispose. No measuring, no drawing from a vial, no guessing about concentration.
| Brand Pen | Dose | Self-Pay Price | Insurance + Card | What's Included |
|---|---|---|---|---|
| Wegovy | 0.25-2.4mg | $199-349/mo | $25/mo | 4 pens/month, pre-set dose |
| Wegovy HD | 7.2mg | $399/mo | $25/mo | 4 pens/month, highest dose |
| Zepbound KwikPen | 2.5-15mg | $299-449/mo | $25/mo | 4 pens/month |
| Ozempic | 0.25-2mg | $349-499/mo | $25/mo | 1 pen/month, multi-dose |
| Mounjaro | 2.5-15mg | $299-449/mo | $25/mo | 4 pens/month |
Pen advantages
Pre-measured doses eliminate measurement errors. Single-use construction reduces contamination risk. FDA-approved formulations with standardized concentration. No cold-chain storage concerns (pens are designed for room-temperature use for limited periods).
Multi-Dose Vials: What You Pay For
Compounded GLP-1 providers typically supply medication in multi-dose vials. You draw your dose using a syringe, inject, and refrigerate the remaining supply. This format enables the dramatically lower pricing that makes compounded GLP-1s affordable.
| Provider | Format | Price/mo | Dose Measurement | Who Measures |
|---|---|---|---|---|
| GobyMeds | Vials | $99/mo sema | Syringes provided | Patient |
| Oak Longevity | Vials | $130/mo sema | Syringes provided | Patient |
| Embody | Vials | $149-299 | Syringes provided | Patient |
| Gala GLP-1 | Vials | $179/mo | Syringes provided | Patient |
Vial advantages
Dramatically lower cost ($99-179 vs $199-449 for pens). Flexible dosing — you can precisely adjust your dose in small increments based on provider guidance. Some patients prefer the control of self-measurement. Compounded vials can contain concentrations not available in brand-name pens.
The Safety Comparison
This is where the format discussion gets serious. The FDA's 455+ adverse event reports for compounded semaglutide are heavily skewed toward multi-dose vial issues: dosing errors (drawing too much or too little), contamination from repeated needle insertion into the vial, and concentration inconsistencies between batches.